Poster – P66 NEUROday 2025

Screen to Cure: SCREEN4PN & MouseKing

Mathijs B. van der Lei (1), Dale J. Annear (1), Nathan Donies (2), Tamira van Wermeskerken (2), Julia Gauglitz (3), Nele Kindt (3), Frank R. Kooy (1) & Vincent Timmerman (2)

- (1) Medical Genetics (MEDGEN), Center for Medical Genetics (CMG), University of Antwerp
- (2) Peripheral Neuropathy Research Group, University of Antwerp
- (3) Valorisation Managers PreMet and Life Sciences, University of Antwerp

Establishing effective therapies for rare neurological diseases remains one of the greatest challenges in molecular medicine. While advances in AI are accelerating drug discovery, efficient preclinical validation remains a major bottleneck. To address this, we developed a standardized drug screening platform that combines SCREEN4PN, an iPSC-based 2D & 3D cell system assay, and MouseKing, a bioinformatics pipeline for next-generation mouse phenotyping using the Live Mouse Tracker. This unified approach enables robust, scalable assessment of therapeutic efficacy and bridges the gap between drug discovery and translational success in drug development.